These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis. Athauda-Arachchi P; Lang C Cardiovasc Ther; 2012 Aug; 30(4):e210-1. PubMed ID: 21884008 [TBL] [Abstract][Full Text] [Related]
24. Conventional and novel drug therapeutics to relief myocardial ischemia. Dvir D; Battler A Cardiovasc Drugs Ther; 2010 Aug; 24(4):319-23. PubMed ID: 20658184 [TBL] [Abstract][Full Text] [Related]
25. Late sodium current inhibition as a new cardioprotective approach. Hale SL; Shryock JC; Belardinelli L; Sweeney M; Kloner RA J Mol Cell Cardiol; 2008 Jun; 44(6):954-967. PubMed ID: 18462746 [TBL] [Abstract][Full Text] [Related]
26. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Villano A; Di Franco A; Nerla R; Sestito A; Tarzia P; Lamendola P; Di Monaco A; Sarullo FM; Lanza GA; Crea F Am J Cardiol; 2013 Jul; 112(1):8-13. PubMed ID: 23558043 [TBL] [Abstract][Full Text] [Related]
27. Ranolazine: a review of its use in chronic stable angina pectoris. Keating GM Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575 [TBL] [Abstract][Full Text] [Related]
28. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Wenger NK; Chaitman B; Vetrovec GW Am J Cardiol; 2007 Jan; 99(1):11-8. PubMed ID: 17196454 [TBL] [Abstract][Full Text] [Related]
30. Ranolazine (ranexa) for chronic angina. Med Lett Drugs Ther; 2006 Jun; 48(1236):46-7. PubMed ID: 16770296 [No Abstract] [Full Text] [Related]
31. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Rupp H; Zarain-Herzberg A; Maisch B Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634 [TBL] [Abstract][Full Text] [Related]
32. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders. Bhandari B; Subramanian L Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101 [TBL] [Abstract][Full Text] [Related]
33. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Anderson JR; Nawarskas JJ Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056 [TBL] [Abstract][Full Text] [Related]
34. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Chaitman BR Circulation; 2006 May; 113(20):2462-72. PubMed ID: 16717165 [No Abstract] [Full Text] [Related]
35. Expanding the understanding of the treatment of chronic angina: a 21st century approach--part 1. Conti CR Clin Cardiol; 2008 Jun; 31(6):239-40. PubMed ID: 18543302 [TBL] [Abstract][Full Text] [Related]
39. Myocardial metabolism: a new target for the treatment of heart disease? Taegtmeyer H; Salazar R Curr Hypertens Rep; 2004 Dec; 6(6):414-5. PubMed ID: 15527683 [No Abstract] [Full Text] [Related]
40. The evolving role of medical therapy for chronic stable angina. Eid F; Boden WE Curr Cardiol Rep; 2008 Jul; 10(4):263-71. PubMed ID: 18611360 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]